Hims & Hers HealthHIMSRevenue: is the business selling more than it used to?
$2.3B+59% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $2.3B in 2025, compounding +65% a year since 2022 though the pace has cooled. The last twelve months (+28%) ran below that pace, so growth is slowing. The trailing twelve months are already running at $2.6B, ahead of the last full year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSNet income: how much of that revenue becomes profit?
$128M+2% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $128M in 2025, against $126M the year before. Earnings per share moved -173% over the last twelve months. Trailing twelve-month profit stands at $-142M.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSHow fast is it growing, year by year?
+59.0%revenue growth, FY 2025
→Revenue grew +59% in 2025 against a five-year average of +74%. Earnings grew more slowly (+2%), so costs are absorbing part of the growth.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSRevenue per share: is your slice growing as fast as the company?
$9.09revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Revenue per share reached $9.09 in 2025, compounding +52% a year against +65% for HIMS as a whole. Dilution absorbed about 12.3 points of that growth. Free cash flow per share stands at $0.22.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSFree cash flow: what is left in real cash after everything?
$57M−71% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Free cash flow was $57M in 2025. The trailing twelve months stand at $62M.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSWhere does each dollar of revenue actually go?
→Of $2.3B in 2025 sales, $128M reaches net profit - 5 cents on the dollar. The largest single deduction is running the company ($1.6B).
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→2 cents of every sales dollar became free cash in 2025, up 9 points since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→The biggest claim on each sales dollar is capital spending, at 10% of revenue (stock compensation 6%). That share has risen since 2022, so the cost of competing is climbing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→Operating margin widened 18 points to 4% since 2022. After everything, 5 cents of each sales dollar reaches net profit.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-06-30), not a full fiscal year
→ROE of -44% and ROCE of 6% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSWhat has the market paid for HIMS over time?
2.5xP/S today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 2.5x sales, the market is paying 12% less than HIMS's own 7-year median of 2.8x. Pessimism is priced in - the question is whether it is deserved.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSWhat cash return does the business throw off per dollar of market value?
1.0%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 1.0% of annual free cash flow, less than its 7-year median of -0.7% - you are paying up for the same cash.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSCould it handle its debt if things went wrong?
→Debt isn't clearly tagged in HIMS's filings, so treat the balance sheet with extra care rather than assuming zero.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSIs the company's own capital growing?
→The company's own capital shrank from $344M in 2023 to $324M (-6%). Buybacks or losses are drawing the buffer down - the distinction matters.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSHow much goes back, and how much leaks out as stock comp?
→Shareholders received $90M in buybacks in 2025. Stock compensation issued $135M of new shares in the same year, offsetting 100% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSHow fast is your ownership being diluted - or concentrated?
→The share count grew 9.0% in 2025, averaging 8.2% a year over three years. Your slice of the company shrinks by that much each year unless earnings grow faster.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSDoes HIMS earn more on its capital than that capital costs?
→HIMS earns 6.0% on the capital it employs, below the 10% most investors treat as the cost of capital.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSHIMS has issued or retired shares - did shareholders end up better off?
→HIMS's share count rose +643% from 2019 to 2025 while revenue per share grew +283%. Holders are further ahead than before, though the gain per share is smaller than the growth in the business.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30
Hims & Hers HealthHIMSAre the people running it buying or selling?
→Insiders sold $7M on the open market and bought nothing. Many sales are pre-scheduled diversification rather than a view on the price. A further 46 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-06-30